These results highlight the therapeutic relevance of targeting the leptin–STAT3–AQP1 axis and suggest that Rha is a promising candidate for treating patients with TNBC, particularly in the context of obesity. Here, DHX9 is linked to obesity due to melanocortin 4 receptor deficiency.